| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Advaxis Inc. | AL101 - (TENACITY) | Triple negative breast cancer | Phase 2 | Intravenous | Oncology | |
| Advaxis Inc. | Aspacytarabine (BST-236) | Acute myeloid leukemia (AML) | Phase 2 | Intravenous | Oncology | |
| Adverum Biotechnologies Inc. | Lxo-vec (ixoberogene soroparvovec, ADVM-022) - (OPTIC) | Wet age-related macular degeneration (Wet-AMD) | Phase 2 | Data Released | Intravitreal injection | Opthalmic |
| Adverum Biotechnologies Inc. | Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS) | Wet age-related macular degeneration (AMD) | Phase 3 | Ongoing | Intravitreal injection | Opthalmic |
| Adverum Biotechnologies Inc. | Ixoberogene soroparvovec (Ixo-vec) - (INFINITY) | Diabetic macular edema (DME) | Phase 2 | Trial Discontinued | Intravitreal injection | Opthalmic |
| Adverum Biotechnologies Inc. | Lxo-vec (ixoberogene soroparvovec, ADVM-022) - (OPTIC) | Wet age-related macular degeneration (Wet-AMD) | Phase 2 | Data Released | Intravitreal injection | Opthalmic |
| Adverum Biotechnologies Inc. | Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (AQUARIUS) | wet AMD | Phase 3 | Trial Planned | Intravitreal injection | Opthalmic |
| Adverum Biotechnologies Inc. | Ixoberogene soroparvovec (Ixo-vec) - (INFINITY) | Diabetic macular edema (DME) | Phase 2 | Trial Discontinued | Intravitreal injection | Opthalmic |